Abstract
Patients with moderate-to-severe plaque psoriasis have greatly benefited from the availability of biologics. However, treatment-selection can be challenging and it is important that with growing numbers of biologics available, head-to-head trials comparing efficacy and safety outcomes are undertaken. Most head-to-head trials comparing newer classes of biologics to tumour necrosis factor-α inhibitors have compared with etanercept, which is less commonly used than adalimumab.
Original language | English |
---|---|
Pages (from-to) | 220-221 |
Journal | British Journal of Dermatology |
Volume | 183 |
Issue number | 2 |
Early online date | 13 Feb 2020 |
DOIs | |
Publication status | Published - 2 Aug 2020 |